GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

“The impact on not just kidney disease but also cardiovascular disease and on all-cause death.” Ozempic and other semaglutide ...

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

risk of heart attacks and strokes. The FDA said Ozempic can be used to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular events in patients with type 2 ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, ...

The FDA's decision means Ozempic can now be used to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in patients with both chronic kidney disease ...